Steve Joins Oncorus at an exciting time in the companies scientific and operational endeavors, bringing with him more than 30 years of diverse operational experience in biotech, pharmaceuticals and in-vitro diagnostics. He served successfully in a variety of senior business and operational leadership roles based in Europe and the U.S. The last 15 years at Executive Committee level split between Public and Private companies.
Steve has consulted with a number of early stage biotech companies on the challenges of operational scale-up to meet growth challenges. Seen as a key player in this space among the Cambridge biotech community.
He joined Moderna Inc. when the company was in a nascent state, his 6 years with them pivotal to driving the successful scale up of this fast paced, hyper-growing biotech ‘unicorn’ holding Executive Committee positions responsible for Clinical and non-Clinical Manufacturing operations, Supply Chain, Facilities & HR. finally retiring when Moderna went public.
Prior to joining Moderna, based in France he held the position of SVP Global Operations at bioMérieux SA, he was responsible for 3,500 employees over multiple highly regulated global functions (Regulatory, Information Technology, Internal Control and Quality) and all global Manufacturing sites (15). In addition to his operational duties Steve also held two board level positions in joint ventures (Japan and China).
In his earlier years Steve held many leadership roles within Eli Lilly and Company (UK, Spain & USA), where work experiences covered many different dimensions including finance, manufacturing, sales, HR and people development all in highly regulated environments. Providing solid credentials in business and operations from very early in his career.
Throughout Steve has demonstrated a clear capability to manage depth, complexity and range holding senior leadership positions driving strategic direction and performance in many different functions and geographies. He has continually refined and reengineered infrastructure, organizations and internal processes driving transformation in response to new business challenges.
How do I contact Stephen Harbin?
Has Stephen Harbin been buying or selling shares of Oncorus?
Stephen Harbin has not been actively trading shares of Oncorus over the course of the past ninety days. Most recently, on Tuesday, November 16th, Stephen Harbin bought 15,000 shares of Oncorus stock. The stock was acquired at an average cost of $5.80 per share, with a total value of $87,000.00. Learn More on Stephen Harbin's trading history.
Who are Oncorus' active insiders?
